Kowa Company Limited

National Agriculture and Food Research Organization

Hitachi, Ltd.

Asahi Kasei Chemicals Corporation

The Tokyo Electric Power Company, Incorporated

Takayuki Matsuda

Kimiyuki Shibuya

Sayaka Kurobuchi

Tadaaki Ohgiya

Ayumu Okuda

Yuki Yamaguchi

Minoru Koura

Yuichiro Watanabe

Yoshinori Kyotani

Hiromichi Shigyo

Masao Ohkuchi

Tomoyuki Koshi

Takashi Enomoto

Toru Miura

Takahiro Kitamura

Hideo Yoshizaki

Hisashi Sumida

Kyoko Kotaki

Koichi Yamazaki

Tsunenori Kameda

Taiyo Yoshioka

Akimune Asanuma

Natsuyo Kumai

Yuriko Habata

Ryoko Ichiki

Hideaki Takahashi

Yukiyoshi Yamazaki

Soichi Oda

Kyoko Yasuoka

Hidefumi Ozawa

Yoshiji Nii

Haruo Nohara

Hisanao Yamamoto

Ayako Tosaka

Yuuichirou Watanabe

Tomoko Furuyama

Yoichi Yamazaki

Atsushi Ito

Sayaka (deceased) Kurobuchi

A nest material useful in bagworm rearing is provided which can be stably supplied, is hygienic, and has high efficiency for nest building. A bagworm nest material including a bark having a specific shape and size in accordance with the stage of growth of a bagworm is also provided.

Bag worm nest material

A simple and efficient breeding method for the bagworm moth is provided, as well as a device for performing the method. Also developed and provided is a method of easily collecting eggs from a bagworm moth, an egg collection device for bagworm moths composed of a tubular container. A bagworm moth breeding method and egg collection method performed using the device are also described.

Egg collection device for bagworm moth and breeding method and egg collection method of bagworm moth using the same

[Object] It is to provide a novel LXR&#x3b2; agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C&#x2014;R; each X and Y independently show CH, C&#x2550;O, SO, etc; Z shows CH or N; each R, Rand Rindependently show a hydrogen atom, Calkyl group, etc.; Rshows Calkyl group; Rshows an optionally substituted Caryl group or an optionally substituted 5- to 11-membered heterocyclic group; Rand Rshow a hydrogen atom, etc.; L shows a Calkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

Carbinol derivatives having heterocyclic linker

Monohydrochloride acid addition salts of a polyacidic basic compound, or a water adduct having basic site(s) stronger than pyridine. These monohydrochlorides can be produced by reacting a polyacidic basic compound with an acid salt of pyridine.

Method for preparing acid addition salts of polyacidic basic compounds

There is provided a novel LXR&#x3b2; agonist useful as a preventative and/or therapeutic agent for arteriosclerosis; arteriosclerosis such as those resulting from diabetes; hyperlipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate.

Substituted carbinol compound

[Object] To provide a novel LXR&#x3b2; agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate. 

Carbinol derivatives having cyclic linker

To provide a novel LXR&#x3b2; agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate. 

Quinoline compounds

The object is to provide a novel LXR&#x3b2; agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate. 

1,3-dihydroisobenzofuran derivatives

A thermosetting resin compositing having an essential component (A) organopolysiloxane containing a compound represented by following general formula (1) or (2) and optical semiconductor peripheral material using the composition. [Herein, in the formulas, Rindependently represents a substituted or non-substituted monovalent hydrocarbon radical with the carbon number of 1 to 10, Rrepresents an epoxy group-containing organic group, Rrepresents Ror R, a independently represents an integer of 2 or more, b independently represents an integer of 0 or more, X represents general formula (3), Y represents -o- or a bivalent hydrocarbon radical with the carbon number of 1 to 6, Z represents following formula (4), Rin the formula independently represents a substituted or non-substituted monovalent hydrocarbon radical with the carbon number of 1 to 10, and c represents an integer of 0 or more.]

Thermosetting resin composition and semiconductor sealing medium

To provide a novel LXR&#x3b2; agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate. 

2-oxochromene derivatives

This invention relates to a method for preparing an acid addition salt of a polyacidic basic compound, or a water adduct having basic site(s) stronger than pyridine. The method comprises reacting the polyacidic basic compound with an acid salt of pyridine. By the present invention, the number of moles of an added acid in the acid addition salt of the polyacidic basic compound can be readily changed to a number suited for the polyacidic basic compound as needed.

Process for producing acid adduct salt of polyacidic base compound

The present invention is directed to a 2,4-bis(trifluoroethoxy)pyridine compound represented by formula (1): (wherein Xrepresents a fluorine atom or a hydrogen atom) or a salt thereof, and to a drug containing the compound or the salt as an active ingredient. The compound has metabolic resistance in human liver microsome, good absorbability upon oral administration, and excellent ACAT inhibitory activity.

2,4-bis (trifluoroethoxy)pyridine compound and drug containing the compound

Pyridazin-3-one derivatives and medicines containing the same

Phenylpyridazine compounds and medicines containing the same

Pyridazine derivatives and drugs containing the same as the active ingredient

Growing community of inventors

Tokyo, Japan

Takayuki Matsuda